Free Trial

Kiromic BioPharma Q4 2023 Earnings Report

Kiromic BioPharma EPS Results

Actual EPS
-$4.16
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Kiromic BioPharma Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Kiromic BioPharma Announcement Details

Quarter
Q4 2023
Time
N/A

Conference Call Resources

Remove Ads

Kiromic BioPharma Earnings Headlines

Trump to unlock 15-figure fortune for America (May 3rd) ?
We were shown this map by former Presidential Advisor, Jim Rickards, one of the most politically connected men in America. Rickards has spent his fifty-year career in the innermost circles of the U.S. government and banking. And he believes Trump could soon release this frozen asset to the public.
Kiromic BioPharma Files for Chapter 7 Bankruptcy
Kiromic says Deltacel-01 trial patient reaches progression-free survival
See More Kiromic BioPharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Kiromic BioPharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Kiromic BioPharma and other key companies, straight to your email.

About Kiromic BioPharma

Kiromic BioPharma (NASDAQ:KRBP), a clinical stage biotherapeutics company, utilizes engineered and non-engineered Gamma Delta T cell (GDT) technologies to develop therapies for solid tumors. The company develops Deltacel-01, which is in Phase 1 clinical trial, for patients with non-small cell lung cancer; Isocel in combination with low-dose radiation to treat Mesothelin Isoform 2 positive solid malignancies; ALEXIS-ISO-1, an allogeneic GDT therapy product that targets an isoform of mesothelin; Procel in combination with low-dose radiation to treat PD-L1 positive solid malignancies; and ALEXIS-PRO-1, an allogeneic GDT therapy product that targets PD-L1. It has a license agreement with Longwood University; and a research and development collaboration agreement with Molipharma, S.R.L. The company was formerly known as Kiromic, Inc. and changed its name to Kiromic BioPharma, Inc. in December 2019. Kiromic BioPharma, Inc. was founded in 2006 and is headquartered in Houston, Texas.

View Kiromic BioPharma Profile

More Earnings Resources from MarketBeat